AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 4014126 — intervention group
Group type: COMPARATOR
Intervention: Referred Care (usual medical care sources)
Number of subjects: 2376
Study 4014126 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped Care
Number of subjects: 2376
Study 4014126 — intervention group
Group type: COMPARATOR
Intervention: Referred Care
Number of subjects: 2376
Study 31503241 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced nutrition group
Number of subjects: 82
Study 31503241 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 82
Study 29676584 — intervention group
Group type: EXPERIMENTAL
Intervention: Current practice of ototoxicity management
Number of subjects: 134
Study 27006427 — intervention group
Group type: EXPERIMENTAL
Intervention: Death certificate cause of death
Number of subjects: 1642
Study 25479465 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based KIDSCREEN-52
Number of subjects: 923
Study 25479465 — intervention group
Group type: COMPARATOR
Intervention: Paper KIDSCREEN-52
Number of subjects: 923
Study 22089999 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (n = 16) performing ossicular and tympanic membrane reconstruction on Days 1, 7, 14, and 21
Number of subjects: 30
Study 22089999 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (n = 14) observing the procedure on Days 7 and 14
Number of subjects: 30
Study 22089999 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with the tympanoplasty model
Number of subjects: 30
Study 22089999 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremor indices and students' motivation
Number of subjects: 30
Study 20842168 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein, high-fiber diet (HPHF)
Number of subjects: 89
Study 20842168 — intervention group
Group type: COMPARATOR
Intervention: Standard low-fat, high-carbohydrate diet
Number of subjects: 89
Study 18180631 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-cut Semmes-Weinstein monofilaments
Number of subjects: 36
Study 16164529 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-initiated education programme on osteoporosis prevention
Number of subjects: 0
Study 16164529 — intervention group
Group type: COMPARATOR
Intervention: Control group (no education programme)
Number of subjects: 0
Study 14518528 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitative rehabilitation technique (task 2: support by a trainer to move the paretic hand with visual feedback)
Number of subjects: 2
Study 14518528 — intervention group
Group type: COMPARATOR
Intervention: Repetitive hand grasping (task 1: paretic hand at a rate of 0.5 Hz with eyes closed)
Number of subjects: 2
Study 10552979 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg), Amoxycillin (1 g), Metronidazole (400 mg) bd for 7 days (OAM)
Number of subjects: 30
Study 10552979 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg), Clarithromycin (250 mg), Metronidazole (400 mg) bd for 7 days (OCM)
Number of subjects: 30
Study 8673196 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (experimental school)
Number of subjects: 80
Study 29512972 — intervention group
Group type: EXPERIMENTAL
Intervention: Phyto-caffeine-containing shampoo
Number of subjects: 100
Study 29512972 — intervention group
Group type: COMPARATOR
Intervention: Control shampoo
Number of subjects: 100
Study 29310119 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 250 mg b.i.d. (group B; experimental)
Number of subjects: 37
Study 29310119 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 750 mg b.i.d. (group A; conventional)
Number of subjects: 37
Study 29310119 — intervention group
Group type: COMPARATOR
Intervention: Conventional regimen (group C; normal renal function)
Number of subjects: 37
Study 29310119 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional regimen (group A; conventional)
Number of subjects: 37
Study 27402282 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory relearning (n=52)
Number of subjects: 104
Study 27402282 — intervention group
Group type: COMPARATOR
Intervention: Control (n=52)
Number of subjects: 104
Study 24092834 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate meal
Number of subjects: 8
Study 24092834 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein meal
Number of subjects: 8
Study 24092834 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat meal
Number of subjects: 8
Study 24092834 — intervention group
Group type: COMPARATOR
Intervention: Low-calorie placebo
Number of subjects: 8
Study 23342765 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO2) combined with drugs
Number of subjects: 68
Study 23342765 — intervention group
Group type: COMPARATOR
Intervention: Control group (drugs only)
Number of subjects: 68
Study 23342765 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO2)
Number of subjects: 68
Study 19940079 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitrite (1 micromol/min) during hypoxia
Number of subjects: 18
Study 19940079 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline during hypoxia
Number of subjects: 18
Study 19940079 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitrite (1 micromol/min) during normoxia
Number of subjects: 18
Study 16996660 — intervention group
Group type: EXPERIMENTAL
Intervention: EN supplemented with a mixture of cysteine, threonine, serine and aspartate (AA patients)
Number of subjects: 12
Study 16996660 — intervention group
Group type: COMPARATOR
Intervention: EN supplemented with alanine at isonitrogenous levels (Ala patients)
Number of subjects: 12
Study 16286100 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg daily)
Number of subjects: 67
Study 16286100 — intervention group
Group type: COMPARATOR
Intervention: Hydration and tenoxicam (20 mg orally once daily)
Number of subjects: 67
Study 12145221 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-based protein (PP)
Number of subjects: 17
Study 12145221 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal-based protein (AP)
Number of subjects: 17
Study 9856921 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous recovery of sinus rhythm
Number of subjects: 109
Study 9856921 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous procainamide
Number of subjects: 109
Study 9856921 — intervention group
Group type: COMPARATOR
Intervention: DC shock
Number of subjects: 109
Study 9856921 — intervention group
Group type: EXPERIMENTAL
Intervention: Mode of cardioversion
Number of subjects: 109
Study 9856921 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal left atrial size
Number of subjects: 109
Study 7824108 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% glucose infusion
Number of subjects: 9
Study 7824108 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 9
Study 2228650 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 units of heparin in 1 ml sodium chloride solution
Number of subjects: 32
Study 2228650 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride
Number of subjects: 32
Study 204949 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG sleep variables (REM latency, REM density, sleep efficiency, REM sleep percent, delta sleep percent)
Number of subjects: 0
Study 204949 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG sleep variables (REM activity, intermittent nocturnal awakening)
Number of subjects: 0
Study 204949 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Number of subjects: 0
Study 204949 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG sleep variables (REM latency)
Number of subjects: 0
Study 30948522 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent infusion of levobupivacaine [0.125%] bolus delivered every 2 hours (n=20)
Number of subjects: 40
Study 30948522 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of levobupivacaine [0.125%] (6 mL/hour) (n=20)
Number of subjects: 40
Study 30948522 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent infusion of levobupivacaine [0.125%]
Number of subjects: 40
Study 30948522 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of levobupivacaine [0.125%]
Number of subjects: 40
Study 27013239 — intervention group
Group type: EXPERIMENTAL
Intervention: Demand valve oxygen (DVO)
Number of subjects: 57
Study 27013239 — intervention group
Group type: EXPERIMENTAL
Intervention: O2ptimask
Number of subjects: 57
Study 27013239 — intervention group
Group type: COMPARATOR
Intervention: Simple mask
Number of subjects: 57
Study 27013239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 26386766 — intervention group
Group type: EXPERIMENTAL
Intervention: RenalGuard group (hydration with normal saline solution controlled by the RenalGuard system and furosemide)
Number of subjects: 112
Study 26386766 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal saline solution)
Number of subjects: 112
Study 26386766 — intervention group
Group type: EXPERIMENTAL
Intervention: RenalGuard group
Number of subjects: 112
Study 26386766 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 112
Study 26386766 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 112
Study 23822689 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic index diet
Number of subjects: 0
Study 23822689 — intervention group
Group type: COMPARATOR
Intervention: High glycemic index diet
Number of subjects: 0
Study 23822689 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 0
Study 21315352 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL (25mg once daily)
Number of subjects: 341
Study 21315352 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin (40 mg once daily)
Number of subjects: 341
Study 21315352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 341
Study 19549752 — intervention group
Group type: EXPERIMENTAL
Intervention: high monounsaturated fatty acids (MUFA)/high glycemic index (GI)
Number of subjects: 720
Study 19549752 — intervention group
Group type: EXPERIMENTAL
Intervention: high MUFA/low GI
Number of subjects: 720
Study 19549752 — intervention group
Group type: EXPERIMENTAL
Intervention: low fat (LF)/high GI
Number of subjects: 720
Study 19549752 — intervention group
Group type: EXPERIMENTAL
Intervention: LF/low GI
Number of subjects: 720
Study 19549752 — intervention group
Group type: COMPARATOR
Intervention: reference diet (high saturated fatty acids (SF)/high glycemic index (GI))
Number of subjects: 720
Study 16620697 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound imaging at 1.4 +/- 0.6 months and 12.1 +/- 0.7 months after cardiac transplantation
Number of subjects: 190
Study 16620697 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in cross-sectional area stenosis
Number of subjects: 190
Study 16620697 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cross-sectional area stenosis of 20%
Number of subjects: 190
Study 15567796 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 20 ml (group R, n=33)
Number of subjects: 65
Study 15567796 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine combined with fentanyl (group RF, n=32)
Number of subjects: 65
Study 11046100 — intervention group
Group type: EXPERIMENTAL
Intervention: HOE 140 (bradykinin B(2) receptor antagonist)
Number of subjects: 10
Study 11046100 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (0.5 mg/kg i.v.)
Number of subjects: 10
Study 11046100 — intervention group
Group type: EXPERIMENTAL
Intervention: HOE 140 + Furosemide
Number of subjects: 10
Study 11046100 — intervention group
Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 10
Study 9381993 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil + niacin + cholestyramine
Number of subjects: 100
Study 9381993 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 100
Study 8407392 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy at 75.6 Gy (1.26 Gy twice daily for 6 weeks)
Number of subjects: 39
Study 8407392 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy at 75.6 Gy
Number of subjects: 39
Study 2944668 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant SC infusion of ICI 118630
Number of subjects: 17
Study 2944668 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly SC slow-release depot formulation of ICI 118630
Number of subjects: 17
Study 2944668 — intervention group
Group type: COMPARATOR
Intervention: 250-microgram SC bolus of ICI 118630
Number of subjects: 17
Study 31128948 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin
Number of subjects: 245
Study 31128948 — intervention group
Group type: COMPARATOR
Intervention: Interval cytoreductive surgery without hyperthermic intraperitoneal chemotherapy (HIPEC)
Number of subjects: 245
Study 29869333 — intervention group
Group type: EXPERIMENTAL
Intervention: MiYoga
Number of subjects: 42
Study 29869333 — intervention group
Group type: COMPARATOR
Intervention: Waitlist comparison
Number of subjects: 42
Study 26958932 — intervention group
Group type: EXPERIMENTAL
Intervention: TELE sessions (videoconferencing-based communication)
Number of subjects: 97
Study 24041110 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 202
Study 24041110 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 202
Study 23740156 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-brain radiotherapy (WBRT) alone
Number of subjects: 514
Study 20646472 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-to-side esophagogastric anastomosis (SS group)
Number of subjects: 155
Study 20646472 — intervention group
Group type: COMPARATOR
Intervention: Conventional hand-sewn esophagogastrostomy (HS group)
Number of subjects: 155
Study 20646472 — intervention group
Group type: COMPARATOR
Intervention: Circular stapled esophagogastrostomy (CS group)
Number of subjects: 155
Study 18379802 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-resorbable implant (Reunite osteosynthesis plate by Biomet Inc)
Number of subjects: 32
Study 18379802 — intervention group
Group type: COMPARATOR
Intervention: Metal implant
Number of subjects: 32
Study 18379802 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (bio-resorbable and metal implants)
Number of subjects: 32
Study 16052388 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency endovenous obliteration
Number of subjects: 28
Study 16052388 — intervention group
Group type: COMPARATOR
Intervention: Stripping of the long saphenous vein
Number of subjects: 28
Study 12145070 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% Ropivacaine
Number of subjects: 40
Study 12145070 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Normal Saline)
Number of subjects: 40
Study 10189654 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular morphine sulphate (0.15 mg.kg‐1)
Number of subjects: 40
Study 10189654 — intervention group
Group type: COMPARATOR
Intervention: Codeine phosphate (1.5 mg.kg‐1)
Number of subjects: 40
Study 7780255 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese children
Number of subjects: 59
Study 7780255 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 59
Study 2265301 — intervention group
Group type: EXPERIMENTAL
Intervention: In-the-ear hearing aids
Number of subjects: 244
Study 2265301 — intervention group
Group type: COMPARATOR
Intervention: Behind-the-ear hearing aids
Number of subjects: 244
Study 2265301 — intervention group
Group type: COMPARATOR
Intervention: In-the-canal hearing aids
Number of subjects: 244
Study 2265301 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender comparison (females vs males)
Number of subjects: 244
Study 2265301 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulative tasks
Number of subjects: 244
Study 7320448 — intervention group
Group type: EXPERIMENTAL
Intervention: Domiciliary care by midwives
Number of subjects: 996
Study 7320448 — intervention group
Group type: COMPARATOR
Intervention: Traditional care
Number of subjects: 996
Study 31584939 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal nutrition intervention (nutrition counseling and micronutrient supplements)
Number of subjects: 1100
Study 31584939 — intervention group
Group type: COMPARATOR
Intervention: Control (MNCH program alone)
Number of subjects: 1100
Study 30946495 — intervention group
Group type: EXPERIMENTAL
Intervention: PISCES delivered face to face (F2F)
Number of subjects: 514
Study 30946495 — intervention group
Group type: COMPARATOR
Intervention: PISCES delivered via videoconferencing (VC)
Number of subjects: 514
Study 30946495 — intervention group
Group type: COMPARATOR
Intervention: Standard care with added friendly calls (attention control [AC] group)
Number of subjects: 514
Study 28958502 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib 45 mg/day
Number of subjects: 452
Study 28958502 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib 250 mg/day
Number of subjects: 452
Study 28958502 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Number of subjects: 452
Study 28958502 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib
Number of subjects: 452
Study 25499852 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 0
Study 25499852 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 0
Study 23384077 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower alcohol dose group (mean BAC 0.04%, N = 40)
Number of subjects: 126
Study 23384077 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher alcohol dose group (mean BAC 0.06%, N = 44)
Number of subjects: 126
Study 23384077 — intervention group
Group type: COMPARATOR
Intervention: Control group (mean BAC 0.00%, N = 42)
Number of subjects: 126
Study 21631539 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdependent self-construal
Number of subjects: 0
Study 21631539 — intervention group
Group type: COMPARATOR
Intervention: Independent self-construal
Number of subjects: 0
Study 18056792 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% Intralipid infusion [0.7 ml.kg(‐1).h(‐1) (1.54 g/kg)] for 11 h
Number of subjects: 14
Study 18056792 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline infusion for 11 h (control)
Number of subjects: 14
Study 17263277 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam‐remifentanil group (group I)
Number of subjects: 35
Study 17263277 — intervention group
Group type: COMPARATOR
Intervention: Midazolam‐fentanyl group (group II)
Number of subjects: 35
Study 12728159 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 micro g once daily
Number of subjects: 1207
Study 12728159 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micro g twice daily
Number of subjects: 1207
Study 12728159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1207
Study 12728159 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 1207
Study 12728159 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 1207
Study 11590493 — intervention group
Group type: EXPERIMENTAL
Intervention: PI plus two nucleosides
Number of subjects: 166
Study 11590493 — intervention group
Group type: EXPERIMENTAL
Intervention: PI plus one nucleoside
Number of subjects: 166
Study 11590493 — intervention group
Group type: COMPARATOR
Intervention: Only PI
Number of subjects: 166
Study 11590493 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (PI plus two nucleosides)
Number of subjects: 166
Study 11590493 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy (PI plus one nucleoside)
Number of subjects: 166
Study 11590493 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy
Number of subjects: 166
Study 9305714 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy alone (8 cycles)
Number of subjects: 344
Study 9305714 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (6 cycles) plus radiation therapy
Number of subjects: 344
Study 9305714 — intervention group
Group type: EXPERIMENTAL
Intervention: MSKCC model (> or = 3 adverse factors)
Number of subjects: 344
Study 8371918 — intervention group
Group type: EXPERIMENTAL
Intervention: Apraclonidine 0.5% (3 times daily)
Number of subjects: 69
Study 8371918 — intervention group
Group type: EXPERIMENTAL
Intervention: Apraclonidine 0.25% (3 times daily)
Number of subjects: 69
Study 8371918 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5% (twice daily)
Number of subjects: 69
Study 3092660 — intervention group
Group type: EXPERIMENTAL
Intervention: enprostil 70 micrograms
Number of subjects: 129
Study 3092660 — intervention group
Group type: EXPERIMENTAL
Intervention: enprostil 35 micrograms
Number of subjects: 129
Study 3092660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 30101648 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based risk reduction program
Number of subjects: 136
Study 30101648 — intervention group
Group type: COMPARATOR
Intervention: Educational program about campus resources (active control condition)
Number of subjects: 136
Study 29914095 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (HD) of Ecologic® Barrier (1 × 10^10 CFU per day)
Number of subjects: 81
Study 29914095 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose (LD) of Ecologic® Barrier (2.5 × 10^8 CFU per day)
Number of subjects: 81
Study 29914095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 27893675 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg TUDCA plus UDCA placebo
Number of subjects: 199
Study 27893675 — intervention group
Group type: COMPARATOR
Intervention: 250 mg UDCA plus TUDCA placebo
Number of subjects: 199
Study 24743663 — intervention group
Group type: EXPERIMENTAL
Intervention: Many Men, Many Voices (3MV) intervention
Number of subjects: 0
Study 21993405 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 12000
Study 21993405 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral breast cancer
Number of subjects: 12000
Study 21993405 — intervention group
Group type: EXPERIMENTAL
Intervention: Head and neck cancer
Number of subjects: 12000
Study 21993405 — intervention group
Group type: EXPERIMENTAL
Intervention: Male oesophageal cancer
Number of subjects: 12000
Study 21993405 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose response modelling
Number of subjects: 12000